Citation: David Petillo, Stephen Orey, Aik Choon Tan, Lars Forsgren, Sok Kean Khoo. Parkinsons Disease-related Circulating microRNA Biomarkers——a Validation Study[J]. AIMS Medical Science, 2015, 2(1): 7-14. doi: 10.3934/medsci.2015.1.7
[1] | Sapana Shinde, Sayantoni Mukhopadhyay, Ghada Mohsen, Sok Kean Khoo . Biofluid-based microRNA Biomarkers for Parkinsons Disease: an Overview and Update. AIMS Medical Science, 2015, 2(1): 15-25. doi: 10.3934/medsci.2015.1.15 |
[2] | Vanessa J. White, Ramesh C. Nayak . Re-circulating Phagocytes Loaded with CNS Debris: A Potential Marker of Neurodegeneration in Parkinsons Disease?. AIMS Medical Science, 2015, 2(1): 26-34. doi: 10.3934/medsci.2015.1.26 |
[3] | Cassandra A DeMarshall, Abhirup Sarkar, Robert G Nagele . Serum Autoantibodies as Biomarkers for Parkinsons Disease: Background and Utility. AIMS Medical Science, 2015, 2(4): 316-327. doi: 10.3934/medsci.2015.4.316 |
[4] | Sok Kean Khoo . Biofluid-based Biomarkers for Parkinsons Disease: A New Paradigm. AIMS Medical Science, 2015, 2(4): 371-373. doi: 10.3934/medsci.2015.4.371 |
[5] | Antonio Conti, Massimo Alessio . Proteomics for Cerebrospinal Fluid Biomarker Identification in Parkinsons Disease: Methods and Critical Aspects. AIMS Medical Science, 2015, 2(1): 1-6. doi: 10.3934/medsci.2015.1.1 |
[6] | Michiro Muraki . Soluble Fas ligand, soluble Fas receptor, and decoy receptor 3 as disease biomarkers for clinical applications: A review. AIMS Medical Science, 2022, 9(2): 98-267. doi: 10.3934/medsci.2022009 |
[7] | Margarida Pujol-López, Luis Ortega-Paz, Manel Garabito, Salvatore Brugaletta, Manel Sabaté, Ana Paula Dantas . miRNA Update: A Review Focus on Clinical Implications of miRNA in Vascular Remodeling. AIMS Medical Science, 2017, 4(1): 99-112. doi: 10.3934/medsci.2017.1.99 |
[8] | Alessandro P. Delitala . Autoimmunity in latent autoimmune diabetes in adults. AIMS Medical Science, 2019, 6(2): 132-139. doi: 10.3934/medsci.2019.2.132 |
[9] | Rob NM Weijers . Unraveling the Gordian knot of insulin resistance in type 2 diabetes mellitus. AIMS Medical Science, 2022, 9(3): 424-432. doi: 10.3934/medsci.2022021 |
[10] | Ying Chen, Sok Kean Khoo, Richard Leach, Kai Wang . MTA3 Regulates Extravillous Trophoblast Invasion Through NuRD Complex. AIMS Medical Science, 2017, 4(1): 17-27. doi: 10.3934/medsci.2017.1.17 |
PD | Healthy Controls | PSP | MSA | |
PD = Parkinson’s disease; PSP = progressive supranuclear palsy; MSA = multiple system atrophy; M = Male; F = Female | ||||
Sample size Age Hoehn & Yahr | 16 M 14 F 69.4 ± 9.0 2.2 ± 0.7 | 3 M 4 F 72.3± 3.4 | 2 M 3 F 75.2 ± 8.8 4 ± 1.2 | 2 M 2 F 72.5 ± 17.8 4.5 ± 1.0 |
CTR | MSA | PSP | ||
PD = Parkinson’s disease; CTR = healthy controls; MSA = multiple system atrophy; PSP =progressive supranuclear palsy | ||||
PD miR-1826 miR-450b-3p miR-505 miR-626 | 2.046 −9.355 −1.260 0.326 | 1.055 −2.857 1.316 5.125 | −1.613 −1.920 −1.067 3.918 | |
MSA miR-1826 miR-450b-3p miR-505 miR-626 | 1.939 −3.274 −1.659 −15.698 | −1.702 1.488 −1.405 −1.308 | ||
PSP | miR-1826 miR-450b-3 miR-505 miR-626 | 3.300 −4.874 −1.181 −12.000 |
[1] |
Margis R, Rieder CR (2011) Identification of blood microRNAs associated to Parkinsonis disease. J biotechnol 152: 96-101. doi: 10.1016/j.jbiotec.2011.01.023
![]() |
[2] |
Martins M, Rosa A, Guedes LC, et al. (2011) Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PloS one 6: e25443. doi: 10.1371/journal.pone.0025443
![]() |
[3] | Khoo SK, Petillo D, Kang UJ, et al. (2012) Plasma-based circulating microRNA biomarkers for Parkinson's disease. J Parkinson Dis 2: 321-331. |
[4] |
Cardo LF, Coto E, de Mena L, et al. (2013) Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J Neurol 260: 1420-1422. doi: 10.1007/s00415-013-6900-8
![]() |
[5] | Soreq L, Salomonis N, Bronstein M, et al. (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci 6: 10. |
[6] | Vallelunga A, Ragusa M, Di Mauro S, et al. (2014) Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Front Cell Neurosci8: 156. |
[7] |
Botta-Orfila T, Morato X, Compta Y, et al. (2014) Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease. J Neurosci Res 92: 1071-1077. doi: 10.1002/jnr.23377
![]() |
[8] |
Burgos K, Malenica I, Metpally R, et al. (2014) Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One 9: e94839. doi: 10.1371/journal.pone.0094839
![]() |
[9] |
Khoo SK, Neuman LA, Forsgren L, et al. (2013) Could miRNA expression changes be a reliable clinical biomarker for Parkinson's disease? Neurodegener Dis Manag 3: 455-465. doi: 10.2217/nmt.13.53
![]() |
[10] |
Kroh EM, Parkin RK, Mitchell PS, et al. (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298-301. doi: 10.1016/j.ymeth.2010.01.032
![]() |
[11] |
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. doi: 10.1006/meth.2001.1262
![]() |
[12] |
Warnock DG, Peck CC (2010) A roadmap for biomarker qualification. Nat Biotechnol 28:444-445. doi: 10.1038/nbt0510-444
![]() |
[13] |
Tan AC, Naiman DQ, Xu L, et al. (2005) Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 21: 3896-3904. doi: 10.1093/bioinformatics/bti631
![]() |
[14] |
Paulovich AG, Whiteaker JR, Hoofnagle AN, et al. (2008) The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2: 1386-1402. doi: 10.1002/prca.200780174
![]() |
1. | Zhi Wen, Jie Zhang, Peng Tang, Ning Tu, Ke Wang, Guangyao Wu, Overexpression of miR‑185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson's disease, 2017, 1791-2997, 10.3892/mmr.2017.7897 | |
2. | Zahra Aghili, Navid Nasirizadeh, Adeleh Divsalar, Shahram Shoeibi, Parichehreh Yaghmaei, A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease, 2018, 46, 2169-1401, 32, 10.1080/21691401.2017.1411930 | |
3. | Meire Silva Batistela, Nalini Drieli Josviak, Carla Daniela Sulzbach, Ricardo Lehtonen Rodrigues de Souza, An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases, 2017, 127, 0020-7454, 547, 10.1080/00207454.2016.1209754 | |
4. | Sok Kean Khoo, Biofluid-based Biomarkers for Parkinsons Disease: A New Paradigm, 2015, 2, 2375-1576, 371, 10.3934/medsci.2015.4.371 | |
5. | Robert A. Ollar, Practical Application of microRNA Markers in the Diagnosis of Multiple Sclerosis in the Realm of Routine Clinical Neurology, 2018, 23, 0971-9903, 53, 10.4103/jmgims.jmgims_31_18 |
PD | Healthy Controls | PSP | MSA | |
PD = Parkinson’s disease; PSP = progressive supranuclear palsy; MSA = multiple system atrophy; M = Male; F = Female | ||||
Sample size Age Hoehn & Yahr | 16 M 14 F 69.4 ± 9.0 2.2 ± 0.7 | 3 M 4 F 72.3± 3.4 | 2 M 3 F 75.2 ± 8.8 4 ± 1.2 | 2 M 2 F 72.5 ± 17.8 4.5 ± 1.0 |
CTR | MSA | PSP | ||
PD = Parkinson’s disease; CTR = healthy controls; MSA = multiple system atrophy; PSP =progressive supranuclear palsy | ||||
PD miR-1826 miR-450b-3p miR-505 miR-626 | 2.046 −9.355 −1.260 0.326 | 1.055 −2.857 1.316 5.125 | −1.613 −1.920 −1.067 3.918 | |
MSA miR-1826 miR-450b-3p miR-505 miR-626 | 1.939 −3.274 −1.659 −15.698 | −1.702 1.488 −1.405 −1.308 | ||
PSP | miR-1826 miR-450b-3 miR-505 miR-626 | 3.300 −4.874 −1.181 −12.000 |
PD | Healthy Controls | PSP | MSA | |
PD = Parkinson’s disease; PSP = progressive supranuclear palsy; MSA = multiple system atrophy; M = Male; F = Female | ||||
Sample size Age Hoehn & Yahr | 16 M 14 F 69.4 ± 9.0 2.2 ± 0.7 | 3 M 4 F 72.3± 3.4 | 2 M 3 F 75.2 ± 8.8 4 ± 1.2 | 2 M 2 F 72.5 ± 17.8 4.5 ± 1.0 |
CTR | MSA | PSP | ||
PD = Parkinson’s disease; CTR = healthy controls; MSA = multiple system atrophy; PSP =progressive supranuclear palsy | ||||
PD miR-1826 miR-450b-3p miR-505 miR-626 | 2.046 −9.355 −1.260 0.326 | 1.055 −2.857 1.316 5.125 | −1.613 −1.920 −1.067 3.918 | |
MSA miR-1826 miR-450b-3p miR-505 miR-626 | 1.939 −3.274 −1.659 −15.698 | −1.702 1.488 −1.405 −1.308 | ||
PSP | miR-1826 miR-450b-3 miR-505 miR-626 | 3.300 −4.874 −1.181 −12.000 |